Navigation Links
Smart drug improves survival in older patients with acute myeloid leukemia
Date:11/12/2012

A new study has found Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their disease. The results are from a major phase III Cancer Research UK-funded trial led by Cardiff University.

Of the 1,115 patients who took part in the trial, 68 per cent relapsed on the new treatment within three years, compared with 76 per cent of those who had the standard treatment. And 25 per cent were still alive after three years, compared with 20 per cent of those who had the standard treatment.

The drug called Gemtuzumab Ozogamicin (GO) is part of a new class of 'antibody conjugate' drugs, which involve attaching chemotherapy molecules to antibodies specifically designed to recognise proteins on the surface of cancer cells, thereby targeting the cancer while leaving healthy cells unharmed.

The results of the trial show that adding GO to treatment could improve the effectiveness of chemotherapy without excessively increasing side effects, providing a potential lifeline for older AML patients who are often too frail to tolerate more intensive chemotherapy regimes.

The results are published in the Journal of Clinical Oncology.

Chief investigator Professor Alan Burnett, School of Medicine, said: "These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.

"Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years."

Trial participants were recruited at 149 hospitals around the UK and Denmark. All patients had been recently diagnosed with either AML or high risk myelodysplastic syndrome, which can develop into AML, and the majority were aged over 60. Each patient was randomly assigned to receive one of two standard chemotherapy regimes, either with or without GO.

Kate Law, Cancer Research UK's director of clinical research, said: "In general the outlook for leukaemia patients has improved dramatically in recent decades. But when leukaemia is diagnosed in older people it's much harder to treat and there is a real need for effective treatments that are suitable for this age group.

"Importantly this new trial shows that GO may have particular benefits for patients over 60, who may be unsuitable for other more intensive treatments. This is good news and we are now looking to see if these results can be replicated in younger patients."


'/>"/>

Contact: Professor Alan Burnett
BurnettAK@cardiff.ac.uk
44-292-074-2375
Cardiff University
Source:Eurekalert  

Related medicine news :

1. SMART heart eases heart ache, targets cardiac patients emotional well-being
2. Anxiety Linked to Smarts in Brain Study
3. Well-connected brains make you smarter in older age
4. Infant Smarts Similar With Different Types of Formula: Study
5. The Attilio Group’s TAG™-Simply Faster Taps SmartSales To Accelerate Its Expansion Into National Reach
6. Lauren Sciences LLCs research team at Ben-Gurion University awarded Campbell Foundation grant to develop a V-Smart therapeutic for neuro-HIV
7. Dads Smarts May Mean More to His Sons Success Than His Money
8. Engineering the smart health care of the future
9. Engineers improve blood testing technology with smartphone app, hand-held biosensor
10. Sport makes middle-aged people smarter
11. Smartphones Linked to Sexual Activity in Teens: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Smart drug improves survival in older patients with acute myeloid leukemia
(Date:4/29/2017)... , ... April 29, 2017 , ... ... Company to the list of fine retailers selling biodegradable, hanging flushable wipes dispensers ... a large supermarket chain headquartered in San Antonio, Texas, operates more than 350 ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health ... Association of America (HCAOA). This agreement allows HCAOA members to receive special pricing ... discounts on Accreditation University (AU) educational resources that help prepare HCAOA members for ...
(Date:4/28/2017)... ... 2017 , ... Getting enough sleep affects much more than energy – it also has mental ... sleep can compromise motor reaction time, which can increase the risk of having a car ... following tips from the NSF to help you sleep better and feel better:, ...
(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept that hearing aids ... doesn’t have the stigma it had when great-grandpa wore his hearing aids years ago,” ... a NALA North American Speaker Series (NASS) segment. “He probably wore an ...
Breaking Medicine News(10 mins):
(Date:4/26/2017)... 2017 Phoenix Marketing Solutions ( Phoenix ... its mission of transforming science into clinical practice. During a ... Phoenix,s innovative approach supports the life sciences industry ... advances in science and medicine — which ultimately improves lives. ... in 2002 by Tracy Doyle and Angela ...
(Date:4/24/2017)... , April 24, 2017 SW Safety Solutions, ... and comfort, announces the release of the latest advancement ... most recent example of leading edge nitrile glove technology ... for 200% more tactile grip on wet and oily ... durability. With TracTek and a suite of other advanced ...
(Date:4/21/2017)... PHILADELPHIA , April 21, 2017 Halo ... high throughput biopharmaceutical particle analysis system called the Horizon ... on May 1st. The new system analyzes sub visible ... first time rapid particle screening as early as candidate ... working with leading biopharma contract research organization Elion ...
Breaking Medicine Technology: